menu
    • menu
    [{"orgOrder":0,"company":"Kalbe Genexine Biologics","sponsor":"Genexine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Efineptakin alfa","moa":"IL-7","graph1":"Oncology","graph2":"Phase I","graph3":"Kalbe Genexine Biologics","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Kalbe Genexine Biologics \/ KGBio","highestDevelopmentStatusID":"6","companyTruncated":"Kalbe Genexine Biologics \/ KGBio"},{"orgOrder":0,"company":"Kalbe Genexine Biologics","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Serplulimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Kalbe Genexine Biologics","amount2":0.67000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.67000000000000004,"dosageForm":"Injectable\/Injection","sponsorNew":"Kalbe Genexine Biologics \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Kalbe Genexine Biologics \/ Kalbe Genexine Biologics"},{"orgOrder":0,"company":"Kalbe Genexine Biologics","sponsor":"Genexine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efepoetin Alfa","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Kalbe Genexine Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kalbe Genexine Biologics \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Kalbe Genexine Biologics \/ Kalbe Genexine Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Kalbe Genexine Biologics

    Menu

    Kalbe Genexine Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efepoetin Alfa

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Recipient : Genexine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genexine and KGbio Received the First Market Approval for Novel Long-acting Erythropoietin, Efepoetin Alfa, fr...

                            Details : Efesa (efepoetin alfa) is a bio-better drug for CKD-induced anemia, developed based on hyFc®, Genexine's proprietary long-acting platform technology, which is investigated for the treatment of chronic kidney disease induced anemia in non-dialysis patien...

                            Brand Name : Efesa

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 23, 2023

                            Lead Product(s) : Efepoetin Alfa

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Recipient : Genexine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serplulimab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Shanghai Henlius Biotech

                            Deal Size : $665.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HAN...

                            Details : Under the terms of the agreement, Henlius will be responsible for development and commercialisation of Hansizhuang (serplulimab injection) as a treatment for two indications including ES-SCLC, Henlius' novel anti-PD-1 mAb, in 12 MENA countries.

                            Brand Name : Hansizhuang

                            Molecule Type : Large molecule

                            Upfront Cash : $7.0 million

                            September 12, 2023

                            Lead Product(s) : Serplulimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Shanghai Henlius Biotech

                            Deal Size : $665.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            2024 ACI Convention
                            Not Confirmed

                            Kalbe Genexine Biologics

                            Indonesia arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efineptakin alfa

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Genexine

                            Deal Size : $1,100.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            KGBio and Genexine Signed Immuno-Oncology Drug License Agreement GX-17

                            Details : Through this licensing agreement, KGBio and Genexine aim to develop a and commercialize an immuno-oncology drug GX-I7 (Efineptakin Alpha), namely long-acting interleukin-7 which uses the Genexine hyFc technology platform.

                            Brand Name : GX-I7

                            Molecule Type : Large molecule

                            Upfront Cash : $27.0 million

                            February 18, 2021

                            Lead Product(s) : Efineptakin alfa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Genexine

                            Deal Size : $1,100.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth